创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

GE Qianwei, KONG Linghui, SHAO Liming. Outlook 2024: Boosting Confidence and Promoting the High-quality and Balanced Development of China's Biopharmaceutical Industry[J]. Progress in Pharmaceutical Sciences, 2024, 48(3): 237-附页2. DOI: 10.20053/j.issn1001-5094.2024.03.009
Citation: GE Qianwei, KONG Linghui, SHAO Liming. Outlook 2024: Boosting Confidence and Promoting the High-quality and Balanced Development of China's Biopharmaceutical Industry[J]. Progress in Pharmaceutical Sciences, 2024, 48(3): 237-附页2. DOI: 10.20053/j.issn1001-5094.2024.03.009

Outlook 2024: Boosting Confidence and Promoting the High-quality and Balanced Development of China's Biopharmaceutical Industry

  • In 2023, China's biopharmaceutical industry has undergone a significant transformation driven by independent innovation. In 2024, the biopharmaceutical industry will continue to optimize the industry ecosystem, harmonize diverse needs, and focus on differentiated development. Through multiple rounds of brainstorming roundtables, Shanghai Center for Innovation Drug Discovery and Development (SCIDDD) made the 2024 annual outlook on China's biopharmaceutical industry, proposing that the biopharmaceutical industry needs to boost confidence, seize opportunities amid difficulties, and pursue high-quality and balanced development.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return